XW023X7
Introduction Muscle to New Technology Group 7 with Tixagevimab and Cilgavimab Monoclonal Antibody, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 2 Muscle |
| Approach | 3 Percutaneous |
| Device | X Tixagevimab and Cilgavimab Monoclonal Antibody |
| Qualifier | 7 New Technology Group 7 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Muscle
Muscle tissue, whether skeletal or otherwise, is targeted for Introduction procedures when a New Technology substance is delivered directly into the muscular layer rather than the skin or subcutaneous fat above it. This route is used for agents intended to act locally within muscle or to achieve absorption through a highly vascular tissue bed, and it differs mechanically and pharmacokinetically from more superficial injection routes. Because muscle groups vary widely in size, depth, and blood supply across the body, the specific site chosen can affect both technique and the rate at which the introduced substance takes effect. This code is reserved for substances qualifying as New Technology, such as investigational or recently approved biologic agents, rather than routine intramuscular medications.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Tixagevimab and Cilgavimab Monoclonal Antibody
This value represents the combination of tixagevimab and cilgavimab, two long-acting monoclonal antibodies administered together for pre-exposure prophylaxis against COVID-19 in individuals who may not mount an adequate response to vaccination. It differs from REGN-COV2, which is used for treatment of active infection rather than prevention, and from COVID-19 vaccine codes, since it confers passive antibody protection rather than stimulating the recipient's own immune response.
Qualifier: New Technology Group 7
As a qualifier value, Group 7 marks a code as belonging to the set of new technologies approved for use in the 2020-2021 fiscal year, a period that included a notable expansion of infectious-disease-related add-on codes. The label does not describe what the technology does; that detail sits in the table and other axis values. It is distinguished from adjoining groups solely by its approval-year cohort.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.